TGFβ and cancer metastasis: An inflammation link

Cancer and Metastasis Reviews

Volumn 29, Issue 2, 2010, Pages 263-271

  Yang, Li ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immune; Inflammation; Metastasis; TGF ; Tumor microenvironment; Tumor suppressor

Indexed keywords

NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

CANCER INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INFLAMMATION; METASTASIS; METASTASIS INHIBITION; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

GENES, TUMOR SUPPRESSOR; HUMANS; INFLAMMATION; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 77954557286     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-010-9226-3     Document Type: Review

References (87)

1. Bruna, A., Darken, R. S., Rojo, F., Ocana, A., Penuelas, S., Arias, A., et al. (2007). High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell, 11, 147-160.
2. Watanabe, T., Wu, T. T., Catalano, P. J., Ueki, T., Satriano, R., Haller, D. G., et al. (2001). Molecular predictors of survival after adjuvant chemotherapy for colon cancer. New England Journal of Medicine, 344, 1196-1206.
3. Arteaga, C. L. (2006). Inhibition of TGFbeta signaling in cancer therapy. Current Opinion in Genetics & Development, 16, 30-37.
4. Mundy, G. R. (2002). Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature Reviews. Cancer, 2, 584-593.
5. Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Fujitani, Y., Fujitani, S., et al. (2006). Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes & Development, 20, 3147-3160.
6. Munoz, N. M., Upton, M., Rojas, A., Washington, M. K., Lin, L., Chytil, A., et al. (2006). Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Research, 66, 9837-9844.
7. Forrester, E., Chytil, A., Bierie, B., Aakre, M., Gorska, A. E., Sharif-Afshar, A. R., et al. (2005). Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Research, 65, 2296-2302.
8. Guasch, G., Schober, M., Pasolli, H. A., Conn, E. B., Polak, L., & Fuchs, E. (2007). Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell, 12, 313-327.
9. Massague, J. (2008). TGFbeta in cancer. Cell, 134, 215-230.
10. Padua, D., Zhang, X. H., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., et al. (2008). TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell, 133, 66-77.
11. Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., et al. (2009). A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell, 137, 87-98.
12. Dupont, S., Mamidi, A., Cordenonsi, M., Montagner, M., Zacchigna, L., Adorno, M., et al. (2009). FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell, 136, 123-135.
13. Liu, I. M., Schilling, S. H., Knouse, K. A., Choy, L., Derynck, R., & Wang, X. F. (2009). TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO Journal, 28, 88-98.
14. Yang, L., & Moses, H. L. (2008). Transforming growth factor beta: Tumor suppressor or promoter? Are host immune cells the answer? Cancer Research, 68, 9107-9111.
15. Du, R, Lu, K. V, Petritsch, C., Liu, P., Ganss, R., Passegue, E., et al. (2008). HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell, 13, 206-220.
16. Balkwill, F., & Coussens, L. M. (2004). Cancer: An inflammatory link. Nature, 431, 405-406.
17. Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420, 860-867.
18. Yang, L., Debusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y, et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6, 409-421.
19. Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., et al. (2008). Abrogation of TGFbeta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell, 13, 23-35.
20. Bristow, R G, & Hill, R P. (2008). Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature Reviews. Cancer, 8, 180-192.
21. Thomas, D. A., & Massague, J. (2005). TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell, 8, 369-380.
22. Trapani, J. A. (2005). The dual adverse effects of TGF-beta secretion on tumor progression. Cancer Cell, 8, 349-350.
23. Demotte, N., Stroobant, V., Courtoy, P. J., Van der Smissen, P., Colau, D., Luescher, I. F., et al. (2008). Restoring the association of the T cell receptor with CD8 reverses anergy in human tumorinfiltrating lymphocytes. Immunity, 28, 414-424.
24. Peng, G, Wang, H. Y, Peng, W., Kiniwa, Y, Seo, K. H, & Wang, R. F. (2007). Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity, 27, 334-348.
25. Groh, V., Smythe, K., Dai, Z., & Spies, T (2006). Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nature Immunology, 7, 755-762.
26. Wahl, S. M., Wen, J., & Moutsopoulos, N. (2006). TGF-beta: A mobile purveyor of immune privilege. Immunological Reviews, 213, 213-227.
27. Li, M. O., & Flavell, R. A. (2008). TGF-beta: A master of all T cell trades. Cell, 134, 392-404.
28. Daniel, D., Meyer-Morse, N., Bergsland, E. K., Dehne, K., Coussens, L. M., & Hanahan, D. (2003). Immune enhancement of skin carcinogenesis by CD4+ T cells. Journal of Experimental Medicine, 197, 1017-1028.
29. DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N, et al. (2009). CD4 (+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 16, 91-102.
30. de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell, 7, 411-423.
31. Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., et al. (2010). FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell, 17, 121-134.
32. Inoue, S., Leitner, W W., Golding, B., & Scott, D. (2006). Inhibitory effects of B cells on antitumor immunity. Cancer Research, 66, 7741-7747.
33. Mauri, C., & Ehrenstein, M. R. (2008). The 'short' history of regulatory B cells. Trends in Immunology, 29, 34-40.
34. Markiewski, M. M., DeAngelis, R A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C, et al. (2008). Modulation of the antitumor immune response by complement. Nature Immunology, 9, 1225-1235.
35. Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C., Donaldson, D. D., et al. (2000). NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunology, 1, 515-520.
36. Terabe, M., Matsui, S., Park, J. M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., et al. (2003). Transforming growth factorbeta production and myeloid cells are an effector mechanism through which CD1 d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. Journal of Experimental Medicine, 198, 1741-1752.
37. Terabe, M., & Berzofsky, J. A. (2007). NKT cells in immunoregulation of tumor immunity: A new immunoregulatory axis. Trends in Immunology, 28, 491-496.
38. Serafini, P., Borrello, I., & Bronte, V (2006). Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology, 16, 53-65.
39. Marx, J. (2008). Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science, 319, 154-156.
40. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., & Bronte, V. (2008). Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunological Reviews, 222, 162-179.
41. Gabrilovich, D. I., & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews. Immunology, 9, 162-174.
42. Pollard, J. W (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews. Cancer, 4, 71-78.
43. Condeelis, J., & Pollard, J. W. (2006). Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell, 124, 263-266.
44. Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006). Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Reviews, 25, 315-322.
45. Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454, 436-444.
46. Pollard, J. W (2009). Trophic macrophages in development and disease. Nature Reviews. Immunology, 9, 259-270.
47. Joyce, J. A., & Pollard, J. W (2009). Microenvironmental regulation of metastasis. Nature Reviews. Cancer, 9, 239-252.
48. Mantovani, A. (2009). Cancer: Inflaming metastasis. Nature, 457, 36-37.
49. Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., et al. (2009). Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell, 16, 183-194.
50. Mantovani, A. (2009). The yin-yang of tumor-associated neutrophils. Cancer Cell, 16, 173-174.
51. de Visser, K E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews. Cancer, 6, 24-37.
52. Biswas, S., Chytil, A., Washington, K., Romero-Gallo, J., Gorska, A. E., Wirth, P. S., et al. (2004). Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Research, 64, 4687-4692.
53. Lu, S. L., Herrington, H., Reh, D., Weber, S., Bornstein, S., Wang, D., et al. (2006). Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes & Development, 20, 1331-1342.
54. Bierie, B., Stover, D. G., Abel, T W., Chytil, A., Gorska, A. E., Aakre, M., et al. (2008). Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Research, 68, 1809-1819.
55. Bierie, B., & Moses, H. L. (2009). Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle, 8, 3319-3327.
56. Kitamura, T., Kometani, K., Hashida, H., Matsunaga, A., Miyoshi, H., Hosogi, H., et al. (2007). SMAD4-deficient intestinal tumors recruit CCR1 (+) myeloid cells that promote invasion. Nature Genetics, 39, 467-475.
57. Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., et al. (2004). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science, 303, 848-851.
58. Kim, B. G., Li, C., Qiao, W., Mamura, M., Kasprzak, B., Anver, M., et al. (2006). Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature, 441, 1015-1019.
59. Monteleone, G., Mann, J., Monteleone, I., Vavassori, P., Bremner, R., Fantini, M., et al. (2004). A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem, 279, 3925-3932.
60. Hong, S., Lee, C., & Kim, S. J. (2007). Smad7 sensitizes tumor necrosis factor induced apoptosis through the inhibition of antiapoptotic gene expression by suppressing activation of the nuclear factor-kappaB pathway. Cancer Research, 67, 9577-9583.
61. Maggio-Price, L., Treuting, P., Zeng, W., Tsang, M., Bielefeldt-Ohmann, H., & Iritani, B. M. (2006). Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Research, 66, 828-838.
62. Engle, S. J., Ormsby, I., Pawlowski, S., Boivin, G. P., Croft, J., Balish, E., et al. (2002). Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Research, 62, 6362-6366.
63. Luo, J. L., Tan, W., Ricono, J. M., Korchynskyi, O., Zhang, M., Gonias, S. L., et al. (2007). Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature, 446, 690-694.
64. Lu, T., Tian, L., Han, Y., Vogelbaum, M., & Stark, G. R. (2007). Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proceedings of the National Academy of Sciences of the United States of America, 104, 4365-4370.
65. Lu, S. L., Reh, D., Li, A. G., Woods, J., Corless, C. L., Kulesz-Martin, M., et al. (2004). Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Research, 64, 4405-4410.
66. Hiratsuka, S., Watanabe, A., Aburatani, H., & Maru, Y. (2006). Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biology, 8, 1369-1375.
67. Kruse, J. P., & Gu, W. (2009). Modes of p53 regulation. Cell, 137, 609-622.
68. Hainaut, P., & Hollstein, M. (2000). p53 and human cancer: The first ten thousand mutations. Advances in Cancer Research, 77, 81-137.
69. Farazi, P. A., Zeisberg, M., Glickman, J., Zhang, Y., Kalluri, R., & DePinho, R. A. (2006). Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Research, 66, 6622-6627.
70. Hussain, S. P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W. P., et al. (2000). Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease. Cancer Research, 60, 3333-3337.
71. Hussain, S. P., He, P., Subleski, J., Hofseth, L. J., Trivers, G. E., Mechanic, L., et al. (2008). Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Research, 68, 7130-7136.
72. Ruzankina, Y., Schoppy, D. W., Asare, A., Clark, C. E., Vonderheide, R. H., & Brown, E. J. (2009). Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nature Genetics, 41, 1144-1149.
73. Lee, T. L., Yang, X. P., Yan, B., Friedman, J., Duggal, P., Bagain, L., et al. (2007). A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clinical Cancer Research, 13, 5680-5691.
74. Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008). Tenets of PTEN tumor suppression. Cell, 133, 403-414.
75. Trimboli, A. J., Cantemir-Stone, C. Z., Li, F., Wallace, J. A., Merchant, A., Creasap, N., et al. (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature, 461, 1084-1091.
76. Takaku, K., Oshima, M., Miyoshi, H., Matsui, M., Seldin, M. F., & Taketo, M. M. (1998). Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell, 92, 645-656.
77. Rolny, C., Capparuccia, L., Casazza, A., Mazzone, M., Vallario, A., Cignetti, A., et al. (2008). The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. Journal of Experimental Medicine, 205, 1155-1171.
78. Bodenstine, T. M., & Welch, D. R. (2008). Metastasis suppressors and the tumor microenvironment. Cancer Microenvironment, 1, 1-11.
79. Taylor, J., Hickson, J., Lotan, T., Yamada, D. S., & Rinker-Schaeffer, C. (2008). Using metastasis suppressor proteins to dissect interactions among cancer cells and their microenvironment. Cancer Metastasis Reviews, 27, 67-73.
80. Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., et al. (2007). Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. Journal of Clinical Investigation, 117, 1305-1313.
81. Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A. K., & Flavell, R. A. (2006). Transforming growth factor-beta regulation of immune responses. Annual Review of Immunology, 24, 99-146.
82. Nam, J. S., Terabe, M., Mamura, M., Kang, M. J., Chae, H., Stuelten, C., et al. (2008). An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Research, 68, 3835-3843.
83. Nam, J. S., Terabe, M., Kang, M. J., Chae, H., Voong, N., Yang, Y. A., et al. (2008). Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Research, 68, 3915-3923.
84. Fujita, T., Teramoto, K., Ozaki, Y., Hanaoka, J., Tezuka, N., Itoh, Y., et al. (2009). Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Research, 69, 5142-5150.
85. Budhu, A., Forgues, M., Ye, Q. H., Jia, H. L., He, P., Zanetti, K. A., et al. (2006). Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell, 10, 99-111.
86. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313, 1960-1964.
87. Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., et al. (2008). Stromal gene expression predicts clinical outcome in breast cancer. Natural Medicines, 14, 518-527. (Pubitemid 351655218)